All In Biotech

Drug Trial Radar · NCT05354063

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.

A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 60 Years and Over.

Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Jun 1, 2022

Primary completion

Sep 5, 2022

Study completion Oct 1, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety and preliminary immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese healthy adults aged 60 years and over.

Conditions

  • SARS-CoV-2

Interventions

  • 20 μg dose of SYS6006Biological

    20 μg dose of SYS6006 vaccine IM on day 0 and day 21.

  • 30 μg dose of SYS6006Biological

    30 μg dose of SYS6006 vaccine IM on day 0 and day 21.

  • PlaceboDrug

    Placebo IM on day 0 and day 21.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. adverse events, including solicited and unsolicited eventsTime frame: From the first dose through 30 days following the second dose.
  2. adverse events associated with the study interventionTime frame: From the first dose through 30 days following the second dose.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sir Run Run Hospital Nanjing Medical University

    Nanjing, Jiangsu, China

  • Shulan(hangzhou) Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.